InvestorsHub Logo
Followers 6
Posts 394
Boards Moderated 0
Alias Born 10/07/2015

Re: None

Wednesday, 06/29/2022 9:08:21 AM

Wednesday, June 29, 2022 9:08:21 AM

Post# of 2043
Just throwing it out there,, superiority to Otezla outcome was a secondary outcome measure. Not needed for approval. It would been nice had it been superior in 32 weeks, but people live much longer than that. I suspect once approved, provided it does get approved, patient’s and physicians choice will dominate.

Otezla side effects are huge compared to piclidenodon.

IMO
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CANF News